ATRX Adhera Therapeutics

Adhera Therapeutics Inc. and its wholly-owned subsidiaries, MDRNA Research Inc. (“MDRNA”), Cequent Pharmaceuticals Inc. (“Cequent”), Atossa Healthcare Inc. (“Atossa”), and IThenaPharma Inc. (“IThena”) (collectively “Adhera,” the “Company,” “we,” “our,” or “us”), is an emerging specialty biotech company that, to the extent that resources and opportunities become available, is strategically evolving focus in anticipation of a return to a drug discovery and development company, and a departure from active commercialization and promotion of hypertension treatment options in the U.S. market. Previously throughout most of 2019, Adhera Therapeutics was a commercially focused entity that leveraged innovative distribution models and technologies to improve the quality of care for patients in the United States suffering from chronic and acute diseases with a focus on fixed dose combination therapies in hypertension. These efforts were primarily focused on Prestalia® , a single-pill FDC of perindopril arginine and amlodipine besylate, which we began marketing in June of 2018. Prestalia was developed in coordination with Les Laboratories, Servier, a French pharmaceutical conglomerate, that sells the formulation outside the United States under the brand names Coveram® . Prestalia was approved by the U.S. Food and Drug Administration (“FDA”) in January 2015, and was distributed through our patented DyrctAxess platform.
Company profile
Ticker
ATRX
Exchange
Website
CEO
Nancy R. Phelan
Employees
Incorporated
Location
Fiscal year end
Sector
Industry (SIC)
Former names
Marina Biotech, Inc., MDRNA, Inc., NASTECH PHARMACEUTICAL CO INC
SEC CIK
Corporate docs
IRS number
112658569
ATRX stock data
()
Investment data
Securities sold
Number of investors
Calendar
7 Apr 21
17 Apr 21
31 Dec 21
Financial summary
Quarter (USD) |
Dec 20 | Sep 20 | Jun 20 | Mar 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) |
Dec 20 | Dec 19 | Dec 18 | Dec 17 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Financial data from company earnings reports.
Cash burn rate (estimated) | Burn method: Change in cash | Burn method: Operating income/loss | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 1K | 1K | 1K | 1K | 1K | 1K |
Cash burn (monthly) | (positive/no burn) | 4.08K | 54.67K | 169.75K | 30K | 49K |
Cash used (since last report) | n/a | 14.58K | 195.15K | 605.99K | 107.1K | 174.92K |
Cash remaining | n/a | -13.58K | -194.15K | -604.99K | -106.1K | -173.92K |
Runway (months of cash) | n/a | -3.3 | -3.6 | -3.6 | -3.5 | -3.5 |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
1 Nov 19 | Rhonda L. Stanley | Options to purchase common stock common stock | Grant | Aquire A | No | No | 0.09 | 350,000 | 31.5K | 350,000 |
Institutional ownership Q4 2020
Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.
0.0% owned by funds/institutions
13F holders |
Current |
---|---|
Total holders | 1 |
Opened positions | 0 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares |
Current |
---|---|
Total value | 0 |
Total shares | 1 |
Total puts | 0 |
Total calls | 0 |
Total put/call ratio | – |
Largest owners |
Shares | Value |
---|---|---|
Huntington National Bank | 1 | $0 |
Financial report summary
?Competition
Alnylam PharmaceuticalsContent analysis
?
Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. junior Avg
|
New words:
Air, Airborne, Alabama, alter, Andrew, ANTIDILUTIVE, Assault, attorney, badge, Baker, Bar, Barrasso, Baton, BCF, Campbell, Carlo, Carrere, Chariman, Commendation, Denegre, Entergy, Fort, Freeman, freestanding, gas, gave, host, Howard, instrument, joined, Kucharchuk, Kupperman, Ky, LA, lender, lieutenant, Louisiana, Loyola, memo, military, Monte, NaNbad, notified, notional, OncBioMune, Parkway, Pink, Poitevent, preceeding, quantitative, renew, reset, Rice, Rouge, Sarver, simulation, specialist, subordinate, Subtopic, subtracting, Tilly, Timothy, tracing, traditional, Tulane, twenty, Usdin, Waechter, Walker
Removed:
abandon, abroad, accelerated, accidental, Accountability, acei, adherence, adjust, administered, advisor, advisory, agree, ahead, al, Alzheimer, antihypertensive, antisense, Apotex, arterial, artery, ascribed, asserted, assignment, ATB, authorize, bargaining, benchmark, billion, Bima, binding, bio, blood, body, BP, bpCareConnect, Brinker, broader, build, building, burden, Calhoun, camelot, Canada, cancelled, Cardiol, cardiovascular, celecoxib, center, Ceral, challenger, children, citizen, clearance, climate, cohort, Coll, collective, complexity, complicating, complying, concurrently, confirmed, conformationally, congestive, Consumer, contamination, core, coronary, counseling, created, Curr, David, decide, declaratory, defraud, dementia, denial, detecting, detection, differentiate, direction, discharge, district, diuretic, DNA, driven, drop, easily, element, enrollment, europa, European, executing, expand, export, extending, favorably, fist, force, franchise, frequently, Gechter, gene, generation, govern, growth, Habrdova, halt, heart, higher, HTN, hypercholesterolemia, hypertensive, impair, impede, improper, improved, inconclusive, ineffective, inflammation, informed, injury, interact, interfering, interrupt, JAMA, JL, JNC, judgmental, Jung, kidney, larger, largest, launch, launched, length, lessee, letter, lifestyle, long, Lotrel, markedly, marketable, medication, medicinal, memorialized, metabolite, mg, mobilize, Mohammed, monitoring, mortality, multiple, Nephrol, nonadherence, nonadherent, noncompliance, nonresistant, nucleotide, oncology, Oncotelic, Opin, oral, ordering, OTCQB, owed, Pelouch, peripheral, Persell, pertaining, Petrak, pharmacological, physician, pill, poorly, Portability, positive, post, Precise, preempted, presence, presenting, prevalence, prevention, principle, produce, profile, progressed, promise, promised, promising, promoted, prone, prosecution, ramipril, reach, recommended, refill, Refractory, regimen, regulator, release, reliable, remain, remind, render, repeated, resistant, resolved, resultant, RH, scheme, science, searchable, seizure, serum, settle, show, Siddiqui, similarly, simplified, site, slower, Solar, spectrometry, Stephanie, stop, stopped, Strauch, strength, stroke, study, Sunshine, surprisingly, sustain, sustainable, targeted, targeting, teaching, territory, thirty, titrating, titration, tort, toxic, toxicological, track, transition, treating, trust, turnover, unanticipated, uncontrolled, uncooperative, underwent, undesirable, undetectable, unexpected, unforeseen, unique, unmet, unnecessary, unsuccessful, unwilling, upward, urine, version, viable, vigilance, violate, virtue, voluntary, Vorisek, withdraw, worse, Wunder, Wyeth, yield, yielding, Zelinka
Financial reports
10-K
2020 FY
Annual report
7 Apr 21
NT 10-K
Notice of late annual filing
1 Apr 21
10-Q
2020 Q3
Quarterly report
18 Nov 20
NT 10-Q
Notice of late quarterly filing
16 Nov 20
10-Q
2020 Q2
Quarterly report
19 Aug 20
NT 10-Q
Notice of late quarterly filing
14 Aug 20
10-Q
2020 Q1
Quarterly report
6 Jul 20
NT 10-Q
Notice of late quarterly filing
30 Jun 20
10-K
2019 FY
Annual report
14 Apr 20
NT 10-K
Notice of late annual filing
31 Mar 20
Current reports
8-K
Entry into a Material Definitive Agreement
9 Feb 21
8-K
Entry into a Material Definitive Agreement
5 Nov 20
8-K
Entry into a Material Definitive Agreement
13 Jul 20
8-K
Entry into a Material Definitive Agreement
30 Jun 20
8-K
Departure of Directors or Certain Officers
17 Jun 20
8-K
Departure of Directors or Certain Officers
11 Jun 20
8-K
Other Events
11 May 20
8-K
Entry into a Material Definitive Agreement
11 Feb 20
8-K
Submission of Matters to a Vote of Security Holders
19 Dec 19
8-K
Other Events
17 Dec 19
Registration and prospectus
D
$499.95K in debt / options / securities to be acquired, sold $499.95K, 1 investor
19 Feb 20
SC TO-I/A
Issuer tender offer statement (amended)
26 Sep 19
SC TO-I
Issuer tender offer statement
20 Aug 19
D
$7M in debt, sold $3.24M, 45 investors
11 Jul 19
SC TO-I/A
Issuer tender offer statement (amended)
2 Jul 19
SC TO-I/A
Issuer tender offer statement (amended)
6 Jun 19
SC TO-I
Issuer tender offer statement
28 May 19
S-8
Registration of securities for employees
3 May 19
D
$11M in equity / options / securities to be acquired, sold $1.54M, 9 investors
25 Jul 18
D
$15M in equity / options / securities to be acquired, sold $11.67M, 97 investors
25 Apr 18
Proxies
DEFA14A
Additional proxy soliciting materials
13 Dec 19
DEFA14A
Additional proxy soliciting materials
6 Dec 19
DEF 14A
Definitive proxy
19 Nov 19
PRER14A
Preliminary revised proxy
31 Oct 19
PRE 14A
Preliminary proxy
11 Oct 19
DEF 14A
Definitive proxy
17 Sep 18
PRE 14A
Preliminary proxy
5 Sep 18
DEF 14A
Definitive proxy
20 Apr 17
PRER14A
Preliminary revised proxy
18 Apr 17
PRE 14A
Preliminary proxy
10 Apr 17
Other
UPLOAD
Letter from SEC
11 Nov 19
UPLOAD
Letter from SEC
24 Oct 19
UPLOAD
Letter from SEC
22 Aug 19
UPLOAD
Letter from SEC
6 Jun 19
CT ORDER
Confidential treatment order
4 Mar 18
EFFECT
Notice of effectiveness
15 Jun 17
CORRESP
Correspondence with SEC
13 Jun 17
CT ORDER
Confidential treatment order
29 May 17
EFFECT
Notice of effectiveness
14 May 17
CORRESP
Correspondence with SEC
11 May 17
Ownership
3
Adhera Therapeutics / ANDREW ALBERT KUCHARCHUK ownership change
20 Jul 20
4
Adhera Therapeutics / Rhonda L. Stanley ownership change
5 Nov 19
3
Adhera Therapeutics / Rhonda L. Stanley ownership change
4 Nov 19
4
Adhera Therapeutics / Nancy R. Phelan ownership change
4 Apr 19
4
Adhera Therapeutics / Robert Eric Teague ownership change
17 Jan 19
3
Adhera Therapeutics / Nancy R. Phelan ownership change
24 Oct 18
4
Marina Biotech / Vuong Trieu ownership change
4 Oct 18
3
Marina Biotech / Robert Eric Teague ownership change
25 Sep 18
4
Marina Biotech / Robert Eric Teague ownership change
25 Sep 18
4
Marina Biotech / Robert Jr. Moscato ownership change
16 Jul 18